What is the NeXT Dx™ Test?
The Personalis NeXT Dx™ Test is a comprehensive genomic testing solution that enables physicians to identify potential targeted and/or immunotherapy options, evidence of drug resistance and clinical trial options for patients with solid tumors.
- The test profiles ~20,000 genes
- Whole-exome and transcriptome analysis
- Genomic alterations reported in up to 247 cancer-related genes
- SNVs, indels, CNAs from DNA and fusions from RNA
- Additional biomarkers results reported: MSI, Exome-wide TMB
- Test performed at CAP-CLIA certified laboratory
Physician Resources
• Test requisition form
• Sample return form
• Sample preparation guide
• Physician’s FAQ
• Gene list
• Data sheet
Unique to the NeXT Dx™ Test
Product Features
ACE Technology
Achieve enhanced coverage and uniformity across exomeACE Technology provides augmented coverage of difficult-to-sequence gene regions across the entire exome.
>20,000
Genes sequenced at ~300x• Covers all genes, noncoding introns/exons, promoters, splice sides, UTRs
247
Cancer-related genes sequenced at ≥1000x• >99% specificity for all variant types; 99.5% sensitivity for SNVs at ≥ 5% AF; 98.7% sensitivity for indels at ≥ 10% AF; 97.2% sensitivity for CNAs in samples with ≥ 30%
RNA
Analysis for enhanced fusion detectionSensitivity for the fusion detection is 94.9%
True TMB from Exome
& MSI for immunotherapy decisionsExome-wide TMB is the gold standard (Merino et al., Journal for ImmunoTherapy of Cancer 2020) and is not extrapolated from 247 genes
How Does It Work?
1. Order the
NeXT Dx Test
Fill in test
requisition form
2. Ship Samples
To Personalis
laboratory
3. Receive Report
Within 2-3 weeks
of sample receipt
4. Take Action
Discuss treatment
options with patients
Next-generation Cancer Care: Results Unique to Your Patient
Personalis provides clinicians with clinically-focused cancer test results that maximize the chance of identifying an approved therapy or trial for each patient as well as information that can support the identification of new, advanced biomarkers. These results are unique to the patient’s tumor, cover cancer genes known to be relevant in oncogenesis, and provide more potential treatment options than other limited tests.
For ordering inquiry please contact Personalis at clinical@personalis.com. The NeXT Dx Test is available to order in the US (except NY state), Singapore, Malaysia, Indonesia and Taiwan.
